Duchenne UK is not only the largest funder of DMD research in the UK in the last 5 years. We are also committed to accelerating the pace of research, ensuring that we remove potential obstacles and roadblocks that lie in the path of drug development. It is vital that the research we fund has the potential to translate into clinical trials.
So we work with industry, engage with policy makers and regulators and also fund the doctors, nurses and physiotherapists to run clinical trials. For example we funded the Phase I study of VBP15 in the US. We then co-funded Dr Guglieri at Newcastle, who will be running the VBP15 trial in the UK. We proactively invest in every stage of the drug development timeline:
We support and encourage national and international collaboration to allow researchers and clinicians to collaborate and progress research. We are proud to support the Treat-NMD network and their bi-annual TACT meetings to review potential clinical trials for Duchenne Muscular Dystrophy.
A collaborative project to assist companies with HTARead more
We work with scientists and researchers to look at how to improve the outcomes of clinical trials and ensure companies are using the right measurements to determine whether or not a drug in a clinical trial is working or not.Read more
Expanding Clinical trial capacityRead more
Treat-NMD is an international network of scientists, researchers and clinicians working in the neuromuscular field.Read more
We’ve invested more than £500,000 to fund vital clinical trial posts at leading centres of excellence in the UKRead more
Duchenne UK launches the DMD HubRead more
Developing digital technology to evaluate new approaches to measuring efficacy and safety in clinical trialsRead more
We co-funded a doctor to run clinical trials in the UK. She is now running seven trials and is the Principal Investigator on two new upcoming studies.Read more